ZURA BIO LIMITED Depreciation and Amortization
ZURA BIO LIMITED (ZURA) reported Depreciation and Amortization of $32 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DepreciationDepletionAndAmortization · last filed 2026-08-11
- ZURA BIO LIMITED depreciation, depletion and amortization for the quarter ending 2026-06-30 was -$15.97K.
- ZURA BIO LIMITED depreciation, depletion and amortization for the quarter ending 2026-03-31 was $16.00K, a 77.78% increase year-over-year.
- ZURA BIO LIMITED depreciation, depletion and amortization for the quarter ending 2025-12-31 was $15.00K, a 200.00% increase year-over-year.
- ZURA BIO LIMITED depreciation, depletion and amortization for the quarter ending 2025-09-30 was $33.98K, a 1032.67% increase year-over-year.
- ZURA BIO LIMITED depreciation, depletion and amortization for fiscal 2025 was $49.00K, a 444.44% increase from fiscal 2024.
- ZURA BIO LIMITED depreciation, depletion and amortization for fiscal 2024 was $9.00K.
| Period end | Depreciation, Depletion and Amortization 3 month | Depreciation, Depletion and Amortization 6 month | Depreciation, Depletion and Amortization 6 month as first filed | Depreciation, Depletion and Amortization 9 month | Depreciation, Depletion and Amortization 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$15.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $32.00 10-Q · filed 2026-08-11 | $15.03K derived: sum of 3 quarters · filed 2026-08-11 | $49.01K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | $16.00K 10-Q · filed 2026-05-07 | $31.00K derived: sum of 2 quarters · filed 2026-05-07 | $64.98K derived: sum of 3 quarters · filed 2026-05-07 | $56.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | $15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $48.98K derived: sum of 2 quarters · filed 2026-03-19 | $40.00K derived: sum of 3 quarters · filed 2026-08-11 | $49.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | $33.98K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $25.00K derived: sum of 2 quarters · filed 2026-08-11 | $34.00K 10-Q · filed 2025-11-13 | $39.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | -$8.98K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $20.00 10-Q · filed 2026-08-11 | $20.00K 10-Q · filed 2025-08-14 | $5.02K derived: sum of 3 quarters · filed 2026-08-11 | $8.02K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $9.00K 10-Q · filed 2026-05-07 | $14.00K derived: sum of 2 quarters · filed 2026-05-07 | $17.00K derived: sum of 3 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $8.00K derived: sum of 2 quarters · filed 2026-03-19 | $9.00K 10-K · filed 2026-03-19 | ||
| 2024-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $4.00K 10-Q · filed 2025-11-13 | |||
| 2024-06-30 | $1.00K 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |